Naibec Applies for Clinical Trial of Inflammatory Bowel Disease Treatment in Australia
Naivek announced on the 22nd that it has applied for an Australian clinical trial plan (1b·2a) for its Naivek peptide-based inflammatory bowel disease treatment (NIPEP-IBD·code name NP-201).
Hot Picks Today
"Only Two Per Person" Garbage Bag Crisis Was Just Yesterday... Japan Also Faces Shortage Anxiety
- "Samsung Electronics Employee with 100 Million Won Salary Receiving 600 Million Won Bonus... Estimated Tax Revealed"
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- 'Will Demand Finally Decline Due to High Prices?'... "I'll Just Enjoy Nearby Trips" as Japan and China See a Surge
- "Wore It Once, Then This? White Spots All Over 4.15 Million Won Prada Jacket... 'Full Refund Ordered'"
The target disease is inflammatory bowel disease (such as ulcerative colitis), and the purpose of the clinical trial is to evaluate the efficacy, safety, and tolerability of the NP-201 subcutaneous injection formulation. The clinical trial period is 122 days from the date of approval.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
